1- http://www.invs.sante.fr/surveillance/cancers/estimations_cancers/defau…
2- Matutes E., Owusu-Ankomah K., Morilla R., Garcia Marco J., Houlihan A., Que T.H., Catovsky D. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994 Oct ; 8 (10) : 1640-5
3- Hallek M., Cheson B.D., Catovsky D. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia : a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 Jun 15 ; 111 (12) : 5446-56.
4- Leporrier M. Leucémie lymphoïde chronique. Rev Prat 2008 ; 58 :1861-1867.
5- Catovsky D., Richards S., Matutes E. et al. UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group ; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial) : a randomised controlled trial. Lancet. 2007 Jul 21 ; 370 (9583) : 230-9.
6- Lozanski G., Heerema N.A., Flinn I.W. et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004 May 1;103(9) : 3278-81.
En 5 points
Obésité : suivi d’un patient sous aGLP-1
Cas clinique
La fasciite nécrosante
Mise au point
La périménopause
Mise au point
La sclérose en plaques